Ori Biotech

Executive Summary

Ori Biotech is a UK-based biotechnology company founded in 2015, focused on revolutionizing the manufacturing of cell and gene therapies (CGT) through its proprietary IRO® platform. The platform aims to automate CGT production, enhancing biological performance, increasing throughput, and reducing costs, thereby addressing key manufacturing barriers that limit patient access to these life-saving therapies. With its headquarters in London, Ori Biotech operates at the intersection of cell therapy, gene therapy, and biologics, targeting a critical bottleneck in the commercialization of advanced therapeutics. Despite limited public information on its financials or pipeline, the company's technology has the potential to significantly impact the CGT industry by enabling scalable and reproducible manufacturing. As the CGT market grows, Ori Biotech's automation solutions could become essential infrastructure, positioning the company for strategic partnerships and further investment. The company's progress will depend on its ability to secure commercial validation and navigate the regulatory landscape.

Upcoming Catalysts (preview)

• Q1 2026Series C Funding Round Announcement70% success
• Q3 2026First Commercial Partnership with a Top CGT Developer55% success
• Q4 2026ISO 13485 Certification for IRO Platform80% success